Top 4 Healthcare Stocks Backed by Raymond James Analysts
Raymond James analysts identified top healthcare stocks, including Dyne Therapeutics (DYNE-251 data expected 4Q25), Ocular Therapeutix (SOL-R enrollment visibility improving), Trevi Therapeutics (Phase 2b readout in 1H25), and Tyra Biosciences (Phase 2 data in 2026). All are rated Strong Buy or Outperform.
How this was made
The 30-second read
Why it matters
The list provides fresh analyst sentiment but no new corporate events; its primary effect is to influence short‑term positioning.
Market read
Analyst rankings can drive modest trading activity in the highlighted biotech stocks ahead of upcoming clinical milestones.
What to watch
Potential trial failures or regulatory setbacks could reverse any short‑term upside.
Background
Raymond James published its Current Favorites list for healthcare, selecting one buy‑rated idea per analyst.
Ticker impact
Ocular Therapeutix is highlighted for its Axpaxli Phase 3 studies and upcoming 1Q26 readout.
potential upside as market anticipates positive trial outcomes
Constructive view and Strong Buy rating provide short‑term buying impetus.
Tyra Biosciences is ranked fourth for its 2026 catalysts in bladder cancer and achondroplasia trials.
potential upward pressure as market prices in future data milestones
Inclusion in top‑pick list signals confidence and may attract speculative buying.
Market effects
Highlights broader biotech sector optimism around upcoming trial data.
US biotech equities may see modest gains from analyst endorsements.
Limited to investors tracking US-listed biotech stocks.
Counterpoint
Some investors may wait for actual trial results before committing, viewing the picks as speculative.
Key entities
- Research FirmRaymond James
Equity research firm issuing the analyst rankings.
